373 related articles for article (PubMed ID: 25667102)
21. Scutellarin inhibits RANKL-mediated osteoclastogenesis and titanium particle-induced osteolysis via suppression of NF-κB and MAPK signaling pathway.
Zhao S; Sun Y; Li X; Wang J; Yan L; Zhang Z; Wang D; Dai J; He J; Wang S
Int Immunopharmacol; 2016 Nov; 40():458-465. PubMed ID: 27728897
[TBL] [Abstract][Full Text] [Related]
22. Taxifolin Inhibits Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis of Human Bone Marrow-Derived Macrophages in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo.
Zhang HQ; Wang YJ; Yang GT; Gao QL; Tang MX
Pharmacology; 2019; 103(1-2):101-109. PubMed ID: 30522105
[TBL] [Abstract][Full Text] [Related]
23. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.
Ahn KS; Sethi G; Chaturvedi MM; Aggarwal BB
Int J Cancer; 2008 Oct; 123(8):1733-40. PubMed ID: 18688862
[TBL] [Abstract][Full Text] [Related]
24. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
25. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
26. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Li L; Sapkota M; Kim SW; Soh Y
Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
[TBL] [Abstract][Full Text] [Related]
27. Myricetin prevents titanium particle-induced osteolysis in vivo and inhibits RANKL-induced osteoclastogenesis in vitro.
Wu C; Wang W; Tian B; Liu X; Qu X; Zhai Z; Li H; Liu F; Fan Q; Tang T; Qin A; Zhu Z
Biochem Pharmacol; 2015 Jan; 93(1):59-71. PubMed ID: 25449599
[TBL] [Abstract][Full Text] [Related]
28. Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling.
Zhai Z; Qu X; Yan W; Li H; Liu G; Liu X; Tang T; Qin A; Dai K
Breast Cancer Res Treat; 2014 Feb; 144(1):33-45. PubMed ID: 24481680
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of eugenol on RANKL-induced osteoclast formation via attenuation of NF-κB and MAPK pathways.
Deepak V; Kasonga A; Kruger MC; Coetzee M
Connect Tissue Res; 2015 Jun; 56(3):195-203. PubMed ID: 25405641
[TBL] [Abstract][Full Text] [Related]
30. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhai ZJ; Li HW; Liu GW; Qu XH; Tian B; Yan W; Lin Z; Tang TT; Qin A; Dai KR
Br J Pharmacol; 2014 Feb; 171(3):663-75. PubMed ID: 24125472
[TBL] [Abstract][Full Text] [Related]
31. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
Kim JY; Cheon YH; Oh HM; Rho MC; Erkhembaatar M; Kim MS; Lee CH; Kim JJ; Choi MK; Yoon KH; Lee MS; Oh J
Bone; 2014 Mar; 60():104-11. PubMed ID: 24361669
[TBL] [Abstract][Full Text] [Related]
32. Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis
Yang J; Tang R; Yi J; Chen Y; Li X; Yu T; Fei J
FASEB J; 2019 Jun; 33(6):7261-7273. PubMed ID: 30857415
[TBL] [Abstract][Full Text] [Related]
33. Tenuigenin inhibits RANKL-induced osteoclastogenesis by down-regulating NF-κB activation and suppresses bone loss in vivo.
Yang S; Li X; Cheng L; Wu H; Zhang C; Li K
Biochem Biophys Res Commun; 2015 Oct; 466(4):615-21. PubMed ID: 26392312
[TBL] [Abstract][Full Text] [Related]
34. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effects of melatonin on titanium particle-induced inflammatory bone resorption and osteoclastogenesis via suppression of NF-κB signaling.
Ping Z; Wang Z; Shi J; Wang L; Guo X; Zhou W; Hu X; Wu X; Liu Y; Zhang W; Yang H; Xu Y; Gu Y; Geng D
Acta Biomater; 2017 Oct; 62():362-371. PubMed ID: 28867647
[TBL] [Abstract][Full Text] [Related]
36. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Aggarwal BB
Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513
[TBL] [Abstract][Full Text] [Related]
37. Icariin inhibits RANKL-induced osteoclastogenesis via modulation of the NF-κB and MAPK signaling pathways.
Xu Q; Chen G; Liu X; Dai M; Zhang B
Biochem Biophys Res Commun; 2019 Jan; 508(3):902-906. PubMed ID: 30538045
[TBL] [Abstract][Full Text] [Related]
38. Piperine alleviates osteoclast formation through the p38/c-Fos/NFATc1 signaling axis.
Deepak V; Kruger MC; Joubert A; Coetzee M
Biofactors; 2015; 41(6):403-13. PubMed ID: 26627060
[TBL] [Abstract][Full Text] [Related]
39. Calebin A downregulates osteoclastogenesis through suppression of RANKL signalling.
Tyagi AK; Prasad S; Majeed M; Aggarwal BB
Arch Biochem Biophys; 2016 Mar; 593():80-9. PubMed ID: 26874195
[TBL] [Abstract][Full Text] [Related]
40. Mollugin from Rubea cordifolia suppresses receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorbing activity in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
Baek JM; Kim JY; Jung Y; Moon SH; Choi MK; Kim SH; Lee MS; Kim I; Oh J
Phytomedicine; 2015 Jan; 22(1):27-35. PubMed ID: 25636867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
